0.65Open0.65Pre Close0 Volume2.20K Open Interest45.00Strike Price0.00Turnover75.19%IV9.05%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type0.2611Delta0.0751Gamma64.40Leverage Ratio-0.1049Theta0.0019Rho16.82Eff Leverage0.0187Vega
Qiagen NV Stock Discussion
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
QIAGEN Revolutionizes Cancer Research: New 700-Gene Profiling System Plus Major Partnerships Reshape Genomic Testing
QIAGEN Smashes Q1 Targets: 7% Growth Powers Confident 2025 Outlook Boost
QIAGEN Earnings Triumph: Key Products Surge, Margins Expand as Cash Flow Hits Record
QIAGEN (NYSE: QGEN) has announced significant enhancements to its QIAcuity Digital PCR system, enabling simultaneous analysis of up to 12 targets from a single biological sample, more than doubling its previous capability of five targets. This upgrade is achieved through the new QIAcuity Software 3.1 and the launch of the QIAcuity High Multiplex Probe PCR...
Article from late September…
forensic genealogy
$Qiagen NV (QGEN.US)$
No comment yet